However, long term safety data will still be needed in this class, especially in light of early results from the ORAL Surveillance study in RA which suggested higher rates of major cardiovascular events and malignancies in patients taking tofacitinib compared to TNF inhibitors [42]. Here, TNF is linked to rheumatoid arthritis.